Showing 1188 results
- https://www.novartis.com/news/media-releases/novartis-nomme-patrick-horber-docteur-en-medecine-au-poste-de-president-international-alors-que-marie-france-tschudin-president-innovative-medicines-international-et-chief-commercial-officer-quitte-le-comite-executif-de-novartisAprès près de sept années chez Novartis et plus de quatre années en tant que membre du Comité exécutif de Novartis, Mme Tschudin poursuivra sa carrière de leader en dehors de Novartis Le Dr Horber…
- https://www.novartis.com/news/media-releases/novartis-realise-un-2eme-trimestre-solide-malgre-limpact-sur-le-trimestre-du-generique-de-gleevec-aux-us-nouvelles-positives-importantes-de-linnovation-renforcent-les-perspectives-de-croissanceChiffre d'affaires net du T2 stable (0% tcc[1]), les produits de croissance[2] ayant compensé l'impact du générique de Gleevec Gilenya (USD 811 millions, +17% tcc) a continué de croître à un taux…
- https://www.novartis.com/news/media-releases/novartis-erzielt-im-2-quartal-solide-ergebnisse-trotz-us-generikakonkurrenz-fur-gleevec-im-gesamten-quartal-wichtige-positive-neuigkeiten-zu-innovationen-starken-zukunftige-wachstumsperspektivenDer Nettoumsatz bleibt im zweiten Quartal unverändert (0% kWk[1]), da die Wachstumsprodukte[2] die Einbussen durch Generikakonkurrenz für Gleevec kompensieren Gilenya (USD 811 Millionen, +17%…
- https://www.novartis.com/news/media-releases/novartis-drug-jakavi-recommended-chmp-eu-approval-treat-adults-rare-blood-cancer-polycythemia-veraPolycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (…
- https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-first-il-17a-antagonist-cosentyxtm-secukinumab-moderate-severe-plaque-psoriasis-patientsOffering a new treatment option for patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A[1],[2] Phase III data demonstrated…
- https://www.novartis.com/news/media-releases/novartis-cosentyxtm-first-il-17-inhibitor-receive-eu-approval-first-line-treatment-moderate-severe-psoriasis-patientsCosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
- https://www.novartis.com/news/media-releases/novartis-pharmaceuticals-announces-joint-investment-company-qualcomm-leading-innovation-digital-medicines-physicians-and-patientsNovartis establishing a joint investment company with Qualcomm Ventures, the venture investment group of Qualcomm Incorporated, of up to USD 100 million to support early stage companies with…
- https://www.novartis.com/news/media-releases/novartis-announces-robust-phase-iii-results-qva149-and-nva237-and-submits-regulatory-applications-us-fdaPivotal Phase III results for QVA149 and NVA237 met their primary endpoints and significantly improved lung function in COPD patients[1-5] US trials for QVA149 demonstrated significant…
- https://www.novartis.com/news/media-releases/sandoz-biosimilar-filgrastim-recommended-approval-fda-oncologic-drugs-advisory-committeeOncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
- https://www.novartis.com/news/media-releases/novartis-collaborates-intellia-therapeutics-and-caribou-biosciences-explore-making-medicines-and-drug-discovery-tools-crispr-genome-editing-technologyCollaborations give Novartis access to novel CRISPR technology platforms for the discovery and development of new medicines Intellia Therapeutics collaboration to explore therapeutic options for…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 119
- › Next page